On August 19, the Guangxi Zhuang Autonomous Region Public Resources Trading Center released the "Notice on Publishing the Online Pharmaceutical Trading Situation in Guangxi for the Second Quarter of 2024" (hereinafter referred to as the "Notice"), which disclosed the distribution companies and pharmaceuticals with a delivery rate below 70% for two consecutive months or more during the second quarter of this year, as well as the online trading status of pharmaceuticals and the online trading situation of pharmaceutical submission/distribution companies.

01

The Notice公布了8家今年第二季度药品配送率连续2个月及以上低于70%的配送企业，广西要求这些企业及时进行整改，及时订单确认和网上配送。

At the same time, the Notice also announced 319 drugs with a distribution rate for two consecutive months or more below 70% in the second quarter, involving major varieties such as Angong Niuhuang Pills, Danggui Buxue Oral Liquid, and Compound Danshen Tablets.

According to the specific assessment indicators proposed by China's national medical insurance department for the online procurement rates of drugs and medical consumables in public medical institutions, public medical institutions, as the primary responsible entities for procurement, must strictly enforce the Sunshine Procurement and Centralized Volume-based Procurement policies to ensure that the annual online procurement rate for drugs reaches 90% and the online procurement rate for medical consumables reaches 85%.

02

Top 10 Drugs and Companies by Procurement and Inbound Amount

According to the statistics of Saibailan, the drug with the highest online transaction procurement amount in the second quarter of 2024 in Guangxi was Bevacizumab Injection from Qilu Pharmaceutical, with a procurement amount reaching 31.3369 million yuan. The rest followed in order: Indobufen Tablets from Hangzhou Zhongmei Huadong Pharmaceutical (31.2718 million yuan), Rituximab Injection from Shanghai Fosun Henlius Biopharmaceutical (26.8106 million yuan), etc. The specific situation is as follows:

In the second quarter of 2024, the drug with the highest online transaction入库金额 in Guangxi's Sunshine Listing Drug Program was still Bevacizumab Injection from Qilu Pharmaceutical Co., Ltd., reaching 25.2077 million yuan. The following drugs ranked next: Indobufen Tablets (24.8075 million yuan) from Hangzhou Zhongmei Huadong Pharmaceutical, and Ginkgo Biloba Extract Injection (13.2316 million yuan) from Yuhong Pharmaceutical Group Co., Ltd., among others. Most of the top 10 drugs by入库金额 are from companies in China. The specific situation is as follows:

Note: The TOP drug list by入库amount is attached at the end of the article.

Generally speaking, the warehousing amount refers to the amount calculated by medical institutions on the procurement platform based on purchase orders, according to the winning bid price and quantity. This is also the amount of pharmaceuticals that manufacturers entrust commercial companies to sell to medical institutions. Through this data, one can often see the sales performance of various enterprises' products in Guangxi's medical market.

03

Top 10 Shortage Drugs and Companies by Procurement and Storage Value

In the second quarter of 2024, the drug with the highest online transaction procurement amount in Guangxi's Sunshine Listing Shortage Drugs Platform was Clofazimine Soft Capsules (3.8091 million yuan) produced by Shanxi Liye Pharmaceutical. The rest followed in order as Thiamazole Tablets (2.9693 million yuan) from Merck Pharma (Jiangsu), and Sodium Succinate Hydrocortisone for Injection (1.5958 million yuan) from Yantai Dongcheng Northern Pharmaceutical. Details are as follows:

The drug with the highest入库金额among the shortage drugs is Chlorofluorocapsules (319.5 million yuan) produced by Shanxi Liye Pharmaceutical, followed by Methimazole Tablets (245.97 million yuan) from Merck Pharma (Jiangsu), and Sodium Succinate Hydrocortisone for Injection (131.58 million yuan) from Yantai Dongcheng Northern Pharmaceutical, as detailed below:

Note: A list of drugs with shortages in stock value is attached at the end of the article.

According to the relevant regulations of the "Discretionary Benchmark for Credit Rating of Pharmaceutical Prices and Procurement (2020 Edition)" by the Medical Price and Bidding Procurement Guidance Center of the National Healthcare Security Administration, if pharmaceutical companies engage in fraudulent activities, collude in bidding, abuse market dominance, or otherwise disrupt the centralized procurement order, once established, such actions will be deemed as acts of dishonesty.

In addition, if a pharmaceutical company refuses to perform purchase and sale or distribution contracts without justifiable reasons, and fails to inform the centralized procurement agency and the purchasing entity one month in advance, causing serious impact on the clinical treatment order, its credit rating will be assessed as "Severe," and restrictions or suspension of its online listing, bidding, or distribution qualifications will be imposed.

Guangxi requires that, starting from the next quarter, drugs with a delivery rate of less than 70% for three consecutive months, as well as distribution companies with a delivery rate of less than 70% for two consecutive months or a cumulative three months within two quarters, will have their online listing and distribution qualifications suspended for one year.

By publishing the drugs, enterprises, and medical institutions with low storage rates, Guangxi reminds relevant organizations to promptly confirm the arrival of goods and complete warehousing, further improving the online procurement rate.

Guangxi 2024 Q2 Sunshine Online Shortage Drug Transaction Amount Ranking

—END—

Highlights Review:

2.5 Billion Shortage of Essential Drugs, Sales Drop by More Than 50% After Centralized Procurement

Tasly Soars to Daily Limit Before Market Opens! Gained Control by China Resources Sanjiu for 6.2 Billion

Another老牌中药企业 may change hands

2024 National Reimbursement List Preliminary Review Released: Multiple Key Innovative Drugs Included